These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8719298)

  • 1. Na+, K+ ATPase activity in red cells predicts the recurrence of hyperthyroidism in patients with Graves' disease.
    De Riva C; Virgili F; Frigato F
    J Endocrinol Invest; 1995 Oct; 18(9):683-9. PubMed ID: 8719298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired Na+,K+ATPase activity in red blood cells in euthyroid women treated with levothyroxine after total thyroidectomy for Graves' disease.
    De Riva C; Vircici F
    Metabolism; 1998 Oct; 47(10):1194-8. PubMed ID: 9781620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
    Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
    Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
    García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
    Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease.
    Fukao A; Takamatsu J; Murakami Y; Sakane S; Miyauchi A; Kuma K; Hayashi S; Hanafusa T
    Clin Endocrinol (Oxf); 2003 May; 58(5):550-5. PubMed ID: 12699435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Na+K+ATPase activity and ouabain binding sites in erythrocytes in hyperthyroidism before and after treatment.
    De Riva C; Chen S; Virgili F; Frigato F
    J Endocrinol Invest; 1992 May; 15(5):363-7. PubMed ID: 1324264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.
    Masiello E; Veronesi G; Gallo D; Premoli P; Bianconi E; Rosetti S; Cusini C; Sabatino J; Ippolito S; Piantanida E; Tanda ML; Chiovato L; Wiersinga WM; Bartalena L
    J Endocrinol Invest; 2018 Dec; 41(12):1425-1432. PubMed ID: 29946800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine therapy versus antithyroid medications for Graves' disease.
    Ma C; Xie J; Wang H; Li J; Chen S
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A patient-specific treatment model for Graves' hyperthyroidism.
    Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
    Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Na-K-dependent ATPase in red cells and thyroid status.
    Sato T; Kajiwara S; Miyamori C; Kato T
    Endocrinol Jpn; 1982 Oct; 29(5):631-8. PubMed ID: 6303767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical studies on assay for Na-K ATPase in human blood cells. I. Erythrocyte Na-K ATPase assay in patients with thyroid dysfunction and in those with chronic renal failure].
    Ogasawara H; Nishikawa M
    Nihon Naibunpi Gakkai Zasshi; 1988 May; 64(5):329-39. PubMed ID: 2842203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
    Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
    J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.